Summary | |
---|---|
Symbol | JAK1 |
Name | Janus kinase 1 |
Aliases | JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1 |
Chromosomal Location | 1p32.3-p31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Endomembrane system; Peripheral membrane protein. Note=Wholly intracellular, possibly membrane associated. |
Domain |
PF07714 Protein tyrosine kinase |
Function |
Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway (PubMed:7615558). Kinase partner for the interleukin (IL)-2 receptor (PubMed:11909529). |
Biological Process |
GO:0001525 angiogenesis GO:0001959 regulation of cytokine-mediated signaling pathway GO:0002040 sprouting angiogenesis GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0034340 response to type I interferon GO:0034341 response to interferon-gamma GO:0038083 peptidyl-tyrosine autophosphorylation GO:0038110 interleukin-2-mediated signaling pathway GO:0045088 regulation of innate immune response GO:0045765 regulation of angiogenesis GO:0045766 positive regulation of angiogenesis GO:0046677 response to antibiotic GO:0046777 protein autophosphorylation GO:0048514 blood vessel morphogenesis GO:0060330 regulation of response to interferon-gamma GO:0060333 interferon-gamma-mediated signaling pathway GO:0060334 regulation of interferon-gamma-mediated signaling pathway GO:0060337 type I interferon signaling pathway GO:0060338 regulation of type I interferon-mediated signaling pathway GO:0060759 regulation of response to cytokine stimulus GO:0070669 response to interleukin-2 GO:0071346 cellular response to interferon-gamma GO:0071352 cellular response to interleukin-2 GO:0071357 cellular response to type I interferon GO:1901342 regulation of vasculature development GO:1903670 regulation of sprouting angiogenesis GO:1903672 positive regulation of sprouting angiogenesis GO:1904018 positive regulation of vasculature development |
Molecular Function |
GO:0001664 G-protein coupled receptor binding GO:0004713 protein tyrosine kinase activity GO:0004715 non-membrane spanning protein tyrosine kinase activity GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0005126 cytokine receptor binding GO:0005131 growth hormone receptor binding GO:0019902 phosphatase binding GO:0019903 protein phosphatase binding GO:0031625 ubiquitin protein ligase binding GO:0031730 CCR5 chemokine receptor binding GO:0042379 chemokine receptor binding GO:0044389 ubiquitin-like protein ligase binding GO:0048020 CCR chemokine receptor binding GO:0051427 hormone receptor binding |
Cellular Component |
GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0009898 cytoplasmic side of plasma membrane GO:0019897 extrinsic component of plasma membrane GO:0019898 extrinsic component of membrane GO:0030055 cell-substrate junction GO:0031234 extrinsic component of cytoplasmic side of plasma membrane GO:0098552 side of membrane GO:0098562 cytoplasmic side of membrane |
KEGG |
hsa04151 PI3K-Akt signaling pathway hsa04380 Osteoclast differentiation hsa04550 Signaling pathways regulating pluripotency of stem cells hsa04621 NOD-like receptor signaling pathway hsa04630 Jak-STAT signaling pathway |
Reactome |
R-HSA-170984: ARMS-mediated activation R-HSA-1169410: Antiviral mechanism by IFN-stimulated genes R-HSA-422475: Axon guidance R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-186763: Downstream signal transduction R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-392451: G beta R-HSA-397795: G-protein beta R-HSA-388396: GPCR downstream signaling R-HSA-114604: GPVI-mediated activation cascade R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-109582: Hemostasis R-HSA-2428924: IGF1R signaling cascade R-HSA-6788467: IL-6-type cytokine receptor ligand interactions R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-1169408: ISG15 antiviral mechanism R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-913531: Interferon Signaling R-HSA-909733: Interferon alpha/beta signaling R-HSA-877300: Interferon gamma signaling R-HSA-912526: Interleukin receptor SHC signaling R-HSA-6783783: Interleukin-10 signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-6783589: Interleukin-6 family signaling R-HSA-1059683: Interleukin-6 signaling R-HSA-1266695: Interleukin-7 signaling R-HSA-5683057: MAPK family signaling cascades R-HSA-112411: MAPK1 (ERK2) activation R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-110056: MAPK3 (ERK1) activation R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-169893: Prolonged ERK activation events R-HSA-112409: RAF-independent MAPK1/3 activation R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-912694: Regulation of IFNA signaling R-HSA-877312: Regulation of IFNG signaling R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation |
Summary | |
---|---|
Symbol | JAK1 |
Name | Janus kinase 1 |
Aliases | JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1 |
Chromosomal Location | 1p32.3-p31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between JAK1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between JAK1 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | JAK1 |
Name | Janus kinase 1 |
Aliases | JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1 |
Chromosomal Location | 1p32.3-p31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of JAK1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | JAK1 |
Name | Janus kinase 1 |
Aliases | JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1 |
Chromosomal Location | 1p32.3-p31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of JAK1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of JAK1 in various data sets.
|
Summary | |
---|---|
Symbol | JAK1 |
Name | Janus kinase 1 |
Aliases | JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1 |
Chromosomal Location | 1p32.3-p31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of JAK1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | JAK1 |
Name | Janus kinase 1 |
Aliases | JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1 |
Chromosomal Location | 1p32.3-p31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of JAK1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by JAK1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | JAK1 |
Name | Janus kinase 1 |
Aliases | JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1 |
Chromosomal Location | 1p32.3-p31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of JAK1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | JAK1 |
Name | Janus kinase 1 |
Aliases | JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1 |
Chromosomal Location | 1p32.3-p31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of JAK1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | JAK1 |
Name | Janus kinase 1 |
Aliases | JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1 |
Chromosomal Location | 1p32.3-p31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between JAK1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | JAK1 |
Name | Janus kinase 1 |
Aliases | JAK1A; JTK3; JAK1B; JAK1AB; JAK-1; Tyrosine-protein kinase JAK1 |
Chromosomal Location | 1p32.3-p31.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting JAK1 collected from DrugBank database. |
Details on drugs targeting JAK1.
|